Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPISTENT: Abciximab in Stenting vs Angioplasty
NCT00271401Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 1996
- Primary completion
- Sep 1997
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of abciximab in coronary artery disease (CAD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Composite of Death, Myocardial Infarction, or Urgent Repeat Revascularization at 30 days. Started Jul 1996; status: completed.
02
Drugs
abciximab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00271401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271401.